

# Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G419FE4B566CEN.html>

Date: July 2022

Pages: 51

Price: US\$ 3,500.00 (Single User License)

ID: G419FE4B566CEN

## Abstracts

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor - Drugs In Development, 2022, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 1 and 9 respectively. Similarly, the universities portfolio in Phase II and Discovery stages

comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Cardiovascular which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neuropathic Pain (Neuralgia), Epilepsy, Glaucoma, Ischemic Stroke, Keratitis, Keratoconjunctivitis Sicca (Dry Eye), Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy), Neurodegenerative Diseases, Peripheral Nerve Injury, Radiculopathy, Retinitis Pigmentosa (Retinitis) and Unspecified Ophthalmological Disorders.

Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects

The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and @Scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Overview

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Companies Involved in Therapeutics Development

Asklepios BioPharmaceutical Inc

Biogen Inc

Copernicus Therapeutics Inc

Eli Lilly and Co

Kai Nuo Bio Sci Co Ltd

Kolon Life Science Inc

Lauren Sciences LLC

Neuroptika Inc

Sinfonia Biotherapeutics Inc

Stem Cell Medicine Ltd

Treeway BV

UniQure NV

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Drug Profiles

AMT-090 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs for Neurodegenerative Diseases - Drug Profile

Product Description  
Mechanism Of Action  
EpiRepair - Drug Profile  
Product Description  
Mechanism Of Action  
Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile  
Product Description  
Mechanism Of Action  
Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis and Retinitis  
Pigmentosa - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Gene Therapy to Activate GDNF for Multiple System Atrophy and Parkinson's Disease -  
Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile  
Product Description  
Mechanism Of Action  
KLS-2031 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
LAUR-101 - Drug Profile  
Product Description  
Mechanism Of Action  
LAUR-301 - Drug Profile  
Product Description  
Mechanism Of Action  
NRO-1 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Protein to Activate GDNF for Parkinson's Disease - Drug Profile  
Product Description  
Mechanism Of Action  
ST-502 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

History of Events

TW-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones

Featured News & Press Releases

Jun 18, 2021: CIRM Board approves new clinical trial for ALS

Aug 17, 2020: Neuroptika completes enrollment in phase 2 clinical trial for Dry Eye Disease

Apr 27, 2020: Kolon Life Sciences launches follow-up pipeline to administer the first patient in the US

Jan 17, 2020: Neuroptika enrolls first patient for dry eye disease trial

Apr 30, 2019: Neuroptika announces positive data from NRO-1 phase 1 clinical trial

Mar 11, 2019: Kolon gets FDA nod for testing gene therapy for neuropathic pain

Dec 26, 2018: Neuroptika, Spun Out from Senju Pharmaceutical launches to develop novel regenerative treatment

Dec 26, 2018: Neuroptika, spun out from Senju Pharmaceutical launches to develop novel regenerative treatment

Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients

Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association

Dec 13, 2010: Sangamo Announces Publication Of Data From Program To Develop ZFP Therapeutic For Parkinson's Disease In Journal Of Neuroscience.

Appendix

Methodology

Coverage

Secondary Research

Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Asklepios BioPharmaceutical Inc, 2022

Pipeline by Biogen Inc, 2022

Pipeline by Copernicus Therapeutics Inc, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Kai Nuo Bio Sci Co Ltd, 2022

Pipeline by Kolon Life Science Inc, 2022

Pipeline by Lauren Sciences LLC, 2022

Pipeline by Neuroptika Inc, 2022

Pipeline by Sinfonia Biotherapeutics Inc, 2022

Pipeline by Stem Cell Medicine Ltd, 2022

Pipeline by Treeway BV, 2022

Pipeline by UniQure NV, 2022

Dormant Projects, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G419FE4B566CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G419FE4B566CEN.html>